These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

472 related items for PubMed ID: 19923256

  • 21. Species differences in intestinal metabolic activities of cytochrome P450 isoforms between cynomolgus monkeys and humans.
    Nishimuta H, Sato K, Mizuki Y, Yabuki M, Komuro S.
    Drug Metab Pharmacokinet; 2011 Jun; 26(3):300-6. PubMed ID: 21383522
    [Abstract] [Full Text] [Related]

  • 22. Cytochrome P450 3A-dependent metabolism of a potent and selective gamma-aminobutyric acid Aalpha2/3 receptor agonist in vitro: involvement of cytochrome P450 3A5 displaying biphasic kinetics.
    Ma B, Polsky-Fisher SL, Vickers S, Cui D, Rodrigues AD.
    Drug Metab Dispos; 2007 Aug; 35(8):1301-7. PubMed ID: 17460031
    [Abstract] [Full Text] [Related]

  • 23. Exploration of catalytic properties of CYP2D6 and CYP3A4 through metabolic studies of levorphanol and levallorphan.
    Bonn B, Masimirembwa CM, Castagnoli N.
    Drug Metab Dispos; 2010 Jan; 38(1):187-99. PubMed ID: 19797609
    [Abstract] [Full Text] [Related]

  • 24. Involvement of multiple human cytochromes P450 in the liver microsomal metabolism of astemizole and a comparison with terfenadine.
    Matsumoto S, Yamazoe Y.
    Br J Clin Pharmacol; 2001 Feb; 51(2):133-42. PubMed ID: 11259984
    [Abstract] [Full Text] [Related]

  • 25.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Evaluation of recombinant cytochrome P450 enzymes as an in vitro system for metabolic clearance predictions.
    Stringer RA, Strain-Damerell C, Nicklin P, Houston JB.
    Drug Metab Dispos; 2009 May; 37(5):1025-34. PubMed ID: 19196847
    [Abstract] [Full Text] [Related]

  • 28. Human enteric microsomal CYP4F enzymes O-demethylate the antiparasitic prodrug pafuramidine.
    Wang MZ, Wu JQ, Bridges AS, Zeldin DC, Kornbluth S, Tidwell RR, Hall JE, Paine MF.
    Drug Metab Dispos; 2007 Nov; 35(11):2067-75. PubMed ID: 17709372
    [Abstract] [Full Text] [Related]

  • 29. Expression in yeast, new substrates, and construction of a first 3D model of human orphan cytochrome P450 2U1: Interpretation of substrate hydroxylation regioselectivity from docking studies.
    Ducassou L, Jonasson G, Dhers L, Pietrancosta N, Ramassamy B, Xu-Li Y, Loriot MA, Beaune P, Bertho G, Lombard M, Mansuy D, André F, Boucher JL.
    Biochim Biophys Acta; 2015 Jul; 1850(7):1426-37. PubMed ID: 25857771
    [Abstract] [Full Text] [Related]

  • 30. Inhibition and stimulation of intestinal and hepatic CYP3A activity: studies in humanized CYP3A4 transgenic mice using triazolam.
    van Waterschoot RA, Rooswinkel RW, Sparidans RW, van Herwaarden AE, Beijnen JH, Schinkel AH.
    Drug Metab Dispos; 2009 Dec; 37(12):2305-13. PubMed ID: 19752211
    [Abstract] [Full Text] [Related]

  • 31. Application of Static Modeling --in the Prediction of In Vivo Drug-Drug Interactions between Rivaroxaban and Antiarrhythmic Agents Based on In Vitro Inhibition Studies.
    Cheong EJ, Goh JJ, Hong Y, Venkatesan G, Liu Y, Chiu GN, Kojodjojo P, Chan EC.
    Drug Metab Dispos; 2017 Mar; 45(3):260-268. PubMed ID: 28053220
    [Abstract] [Full Text] [Related]

  • 32.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 33. In vitro inhibition of human small intestinal and liver microsomal astemizole O-demethylation: different contribution of CYP2J2 in the small intestine and liver.
    Matsumoto S, Hirama T, Kim HJ, Nagata K, Yamazoe Y.
    Xenobiotica; 2003 Jun; 33(6):615-23. PubMed ID: 12851038
    [Abstract] [Full Text] [Related]

  • 34. Potential of decursin to inhibit the human cytochrome P450 2J2 isoform.
    Lee B, Wu Z, Sung SH, Lee T, Song KS, Lee MY, Liu KH.
    Food Chem Toxicol; 2014 Aug; 70():94-9. PubMed ID: 24788058
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. In vitro metabolism of terfenadine by a purified recombinant fusion protein containing cytochrome P4503A4 and NADPH-P450 reductase. Comparison to human liver microsomes and precision-cut liver tissue slices.
    Rodrigues AD, Mulford DJ, Lee RD, Surber BW, Kukulka MJ, Ferrero JL, Thomas SB, Shet MS, Estabrook RW.
    Drug Metab Dispos; 1995 Jul; 23(7):765-75. PubMed ID: 7587966
    [Abstract] [Full Text] [Related]

  • 37. Identifying the Dominant Contribution of Human Cytochrome P450 2J2 to the Metabolism of Rivaroxaban, an Oral Anticoagulant.
    Zhao T, Chen Y, Wang D, Wang L, Dong P, Zhao S, Wang C, Meng Q, Sun H, Liu K, Wu J.
    Cardiovasc Drugs Ther; 2022 Feb; 36(1):121-129. PubMed ID: 33411110
    [Abstract] [Full Text] [Related]

  • 38. In vitro studies on the oxidative metabolism of 20(s)-ginsenoside Rh2 in human, monkey, dog, rat, and mouse liver microsomes, and human liver s9.
    Li L, Chen X, Zhou J, Zhong D.
    Drug Metab Dispos; 2012 Oct; 40(10):2041-53. PubMed ID: 22829543
    [Abstract] [Full Text] [Related]

  • 39. Identification of human liver cytochrome P450 enzymes involved in biotransformation of vicriviroc, a CCR5 receptor antagonist.
    Ghosal A, Ramanathan R, Yuan Y, Hapangama N, Chowdhury SK, Kishnani NS, Alton KB.
    Drug Metab Dispos; 2007 Dec; 35(12):2186-95. PubMed ID: 17827338
    [Abstract] [Full Text] [Related]

  • 40. In-vitro metabolism of glycyrrhetinic acid by human and rat liver microsomes and its interactions with six CYP substrates.
    Zhao K, Ding M, Cao H, Cao ZX.
    J Pharm Pharmacol; 2012 Oct; 64(10):1445-51. PubMed ID: 22943175
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 24.